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AbstrAct
In order to evaluate the long-term effect of botulinum toxin type A (BTX) in the treatment 
of hemifacial spasm (HFS), a retrospective analysis of patients treated at the Movement 
Disorders Unit of the Division of Neurology, Clinical Hospital, University of São Paulo, 
School of Medicine from 1993 to 2004 was made. A total of 808 injections with BTX were 
administered to 54 patients with HFS. The mean duration of improvement per application 
was 3.46 months and the mean rate of improvement using subjective judgement by the 
patient was of 83%. Adverse effects, mostly minor, were observed in 64.8% of patients at 
least once along the period of follow-up and the most frequent of them was orbicularis 
oris paralysis (38.8%). There was no decrement in response when compared the first and 
the last injection recorded.
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toxina botulínica tipo A no tratamento do espasmo hemifacial: 11 anos de experiência
resumo
Para avaliar o efeito em longo prazo da toxina botulínica tipo A (TXB) no tratamento do 
espasmo hemifacial (EHF), foi feita uma análise retrospectiva de pacientes tratados no 
Ambulatório de Distúrbios do Movimento da Divisão de Clínica Neurológica - Hospital 
das Clínicas da Faculdade de Medicina da Universidade de São Paulo no período de 
1993 a 2004. Um total de 808 aplicações de TXB foram administradas a 54 pacientes com 
EHF. A duração média de melhora foi de 3,46 meses e a taxa média de melhora segundo 
avaliação subjetiva do paciente foi de 83%. Efeitos adversos, em sua maioria menores, 
foram observados em 64,8% dos pacientes ao menos uma vez durante o seguimento e o 
mais freqüente foi paralisia do orbicular da boca (38,3%). Não se observou decremento na 
resposta quando se comparou a primeira com a última aplicação anotada.
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Hemifacial spasm (HFS), a chronic dis-
order characterized by involuntary and ir-
regular tonic and clonic contractions of the 
muscles supplied by the facial nerve1,2, has 
been known as a clinical entity for centu-
ries3. Until the introduction of botulinum 
toxin (BTX) as a therapeutic alternative for 
HFS, treatment options consisted of oral 
medications with disappointing results, 
and surgical intervention which carries an 
inherent risk of complications1,2. The use of 
BTX type A (BTX-A) in HFS was approved 
by the U.S. Food and Drug Administration 
in 1989 (in Brazil, the use of BTX for the 
treatment of movement disorders was li-
censed in 1992) and since then, in view of 
growing evidence supporting its efficacy2,4-8, 
it has become a standard treatment for HFS.
Arq Neuropsiquiatr 2010;68(4)
 503
Hemifacial spasm: treatment with botulinum toxin type A
Barbosa et al.
Because HFS is a chronic condition that rarely remits 
spontaneously2, it is important to gather information con-
cerning the safety and efficacy of the long-term treat-
ment. To this date, only a small number of studies have 
described the long-term use of BTX in HFS4-8 and none 
of them was in Brazil. The aim of this article is to describe 
our 11-year experience in a tertiary center in Brazil.
Method
Patients
Patients with a diagnosis of HFS receiving treatment 
at the Movement Disorders Clinic of the Division of Neu-
rology, Clinical Hospital, University of São Paulo, School 
of Medicine, between 1993 and 2004 were identified. Pa-
tients with a follow-up of less than one year or who re-
ceived up to 3 injections were excluded from the study. 
From a group of 82 patients who received treatment with 
botulinum neurotoxin type A (Botox®) during this period, 
54 were included in this study. This study was approved 
by the local ethics committee.
Botulinum toxin treatment
The injections were performed according to a mod-
ified scheme proposed by Consky9: 5 points in the mus-
cle orbicularis oculi, 1 point in the muscle corrugator 
supercilii, 3 points in the orbicularis oris and 1 point in 
the muscle mentalis. Sites of injection were sometimes 
changed depending on the effects of the toxin achieved 
after each application, either to enhance its efficacy or 
to decrease collateral effects. The dose at the first appli-
cation was usually 5 units per point around the eye; 4 
units around the mouth and 2 units at the chin. The tox-
in was used within 4 hours after its reconstitution. A vial 
of 100 units freeze dried BTX-A (Botox®) was reconsti-
tuted with 2 ml of preservative free 0.9% saline solution 
to yield toxin in a concentration of 5 units per 0.1 ml. 
The dose for the subsequent injections was sometimes 
modified according to the therapeutic response and tol-
erance. General guidelines used in our service include: us-
age of minimum dose that achieved best efficacy; avoid-
ance of booster injections; longest interval tolerated and 
not shorter than 3 months. In our department the effi-
cacy of each application is routinely evaluated by the pa-
tient based on a scale of subjective degree of functional 
impairment (Columbia University Rating Scale)10 rang-
ing from 0 to 100%; 0% indicates a total lack of improve-
ment with the application and 100% indicates complete 
improvement with return to normal function. Duration 
of the effect is also routinely recorded as reported by the 
patient in terms of duration of maximum effect and not 
including residual effects; because the residual benefit is 
of much longer and variable duration, many times lasting 
for longer than the interval between the injections, only 
the duration of maximum benefit was recorded for this 
study. The interval between injections is of a minimum 
of 3 months in our clinic, and it can be longer according 
to availability of appointments and the duration of effect 
observed on previous injections; the real duration of the 
interval was recorded for this research. BTXA injections 
were performed by six neurologists, either trained or in 
training, during the period of the study.
Medical records review
A retrospective analysis was conducted using the 
medical records of the patients. Past medical history of 
the patients regarding comorbidities and previous use 
of oral medication or surgical procedures was collect-
ed. Data recorded for each application included the dose 
used (in units), the subjective benefit reported by the pa-
tient in the above described scale from 0 to 100%. The in-
terval between each injection was also recorded.  Prev-
alence of collateral effect was recorded in an all-or-none 
variable that would point to its occurrence at least once 
during the treatment, as well as a description of any indi-
vidual collateral effect that occurred.
Statistical analysis
A paired samples t-test was used to compare means. 
A significance value of 0.05 was used throughout. 
ReSULtS
From the initial group of 82 patients, 28 were exclud-
ed from the study (26 received less than 3 injections and 
were followed for less than one year; 1 completed less 
than one year of follow-up; and 1 had incomplete data). 
Fifty-four patients were then included in the analysis 
that will henceforth be commented. The age of the pa-
tients at the beginning of symptoms ranged from 31 to 
79 years and the mean age was 48.3 years (SD 10.8). Most 
of the patients were female (75.9 %). HFS was present on 
the left side in 33 patients (61.1%). Before BTX-A treat-
ment, 32 patients had used oral medication for HFS (19 
had used carbamazepine and 20, benzodiazepines; oth-
er drugs were used by a minority of patients). Only 9 pa-
tients (16.6%) reported some response with oral drugs, 
which was usually mild. 
A total of 808 treatments with multiple sites injec-
tions of BTX-A were administered to 54 patients with 
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HFS in this period. The mean time of follow-up of these 
54 patients studied was 5.88 (SD 3.64) years (range 2-12 
years) with an average of 14.96 (SD 8.99) applications 
per patient. There was a marginally significant difference 
between the average response (mean subjectively rated 
improvement) for the first (83.18%, SD 11.12) and last 
(78.63%, SD 19.23) injection (p=0.052), but no difference 
between the duration of effect in the first (3.42 months, 
SD1.62) and last (3.22 months, SD1.16) injection of BTX 
(p=0.407). None of the patients presented primary or sec-
ondary resistance. Twenty-two patients (40.7%) had a re-
duction of the dose in order to avoid side effects, and only 
6 patients (11.1%) had an increase in the dose. A signifi-
cant difference was found between the amount (in units) 
of BTX in the first (34.47, SD7.41) and last (37.61, SD 
9.37) injections (p=0.02).
Adverse effects, mostly minor, were observed in 64.8% 
of patients at least once along the period of follow-up, the 
most frequent being orbicularis oris paralysis (38.8%), fol-
lowed by ptosis (31.4%) and lagophthalmos (18.5%). 
dISCUSSIoN
This is the first study performed in Brazil on the long-
term use of BTX in HFS, and focuses in our experience 
with botulinum neurotoxin type A (Botox®). In this pa-
tient sample there was a higher number of females than 
males, and a mean age of 48.8 years at symptom presen-
tation. These results are consistent with the results pre-
viously reported by Defazio et al.5, Hsiung et al.6, Pérez-
Saldaña et al.8, Thussu et al.11 and Felicio et al.12. As previ-
ously reported in the literature by Thussu et al.11 and Fe-
licio et al.12, the symptoms were more frequently seen on 
the left side of the face.
There was a statistically significant increase in the 
amount of BTX injected from the first to the last injec-
tion. Hsiung et al.6 also encountered a trend for the in-
crement of dose, but it was not significant. Pérez-Salda-
ña et al.8 reported a progressive increase of BTX dose in 
the first years, but with a subsequent stabilization (differ-
ence was only found among the first four years and be-
tween the seventh and eighth years of follow-up). There 
was no difference between the duration of effect in the 
first and last BTX injections in our series, confirming pre-
vious findings by Defazio et al.5, who also showed no dif-
ference between treatment response in the first and tenth 
year of treatment. Hsiung et al.6 showed maintenance of 
sustained benefit (defined as a continued benefit of 50% 
or more from baseline) with repeated application, but the 
benefit in the second and fifth years of observation was 
respectively 96% and 88%. In our series the difference in 
the rate of improvement reported by each patient after 
the initial and the last injection was marginally signifi-
cant, suggesting that a larger study could provide signifi-
cance to this finding. Nevertheless, in our population no 
cases of primary or secondary resistance were found. This 
could be explained by the lower rate of resistance found 
among patients with HFS than other facial dystonias6.
Local side effects, such as mild facial paresis (lago-
phthalmos or lower facial paralysis), ptosis, diplopia and 
ecchymosis were transitory, disappearing after days or 
weeks. Biglan et al.13 observed that if the total amount 
of BTX (Botox) injected around the eye exceeds 50 units 
(quantity that was not achieved in our patients), there 
was a considerable raise in the risk of lagophthalmos. The 
most frequent side effect in our casuistic was orbicular-
is oris paralysis, which contrasts with the results of other 
groups (that have found ptosis as the most frequent side 
effect)1,5,6,8,14. This finding could be explained by the orbic-
ular oris BTXA injection scheme. Systemic effects of BTX 
were not observed in this population. The rate of adverse 
effects reported here is higher than what is found in pre-
ceding reports5,6,8. This could be partially explained by the 
fact that in our casuistic, any side effect that could be re-
lated to the injection in any moment during follow-up re-
ported by the patients was accounted. Besides, the injec-
tions were sometimes performed by neurologists in train-
ing, which could have contributed to the increase in the 
rate of adverse effects. It must be taken into consideration 
that, in every case, the adverse effect was temporary. The 
frequency of side effects tend to decrease over time5,7,8. 
Five out of 54 patients discontinued treatment in our ser-
vice. However, all of them continued their treatment in 
other public health services or private practices. 
In our series, efficacy was maintained after long peri-
ods of treatment with high degree of patient satisfaction. 
For the treatment of HFS, results indicate that BTX injec-
tions provide very good response rate with sustained ef-
fects while the use of oral medication was highly unsatis-
factory but did not interfere with the response to the BTX 
treatment. Along with previous studies reporting long-
term efficacy of BTX treatment in HFS5,6,8 and in spite 
of the need to raise the amount of BTX injected in the 
period analyzed (which by no means invalidates its effi-
cacy), BTX (and specifically in our case, Botox®) can be 
considered a treatment with prolonged effectiveness in 
HFS. Overall, the results indicated that BTX is safe and 
effective for the treatment of HFS, even in a long-term 
use scenario. 
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